Search Results for: Teva
Teva Pharmaceuticals (TEVA) Q2 2020 earnings: Reaffirms FY20 outlook
Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street's revenue targets. The drug manufacturer reported adjusted EPS of
Corteva Inc. (NYSE: CTVA) Q1 2020 Earnings Call Transcript
Corteva Inc. (CTVA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Megan Britt -- Investor Relations, Contact James (Jim) C. Collins -- Chief Executive
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q1 2020 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Kevin C. Mannix -- Senior Vice President, Investor Relations
Infographic: Teva Pharmaceuticals (TEVA) Q1 2020 earnings results
Teva Pharmaceuticals' (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) swung to a profit in the fourth quarter of 2019 from a loss last year, helped
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
Teva’s Q2 results beat market expectations
Teva Pharmaceutical Industries (NYSE: TEVA) topped revenue and earnings estimates for the second quarter of 2019, giving shares a lift of 1.4%
Earnings preview: Teva’s struggles might not end in Q2
Teva Pharmaceuticals (NYSE: TEVA) is scheduled to report second quarter 2019 earnings results on Wednesday, August 7, before market open. Analysts expect
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company
Earnings preview: New product launches in focus as Teva gets ready for Q1 report
Teva Pharmaceutical (NYSE: TEVA) has long endued uncertainties in business even as the generic drug maker continued its efforts to tackle high
Earnings: Teva Pharma shrinks Q4 losses, but revenue falls
Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56
Earnings Preview: Positive sentiment around Teva
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report fourth-quarter 2018 earnings results on Wednesday, February 13, before market open. Wall Street
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on
Earnings Preview: It’s a mixed bag for Teva Pharma in Q3
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to post its third-quarter 2018 earnings on Nov 1, before the opening bell. So, what
Teva Pharma receives a booster shot with FDA approval
The US FDA on Thursday approved Teva Pharmaceuticals’ (TEVA) generic version of EpiPen and EpiPen Jr auto-injector for the emergency treatment of
Teva Pharmaceuticals shares take a tumble despite earnings beat
Teva Pharmaceutical Industries Ltd. (TEVA) beat market estimates on adjusted EPS for Q2 2018 while revenues came in line with expectations. Despite